Global Kinetics Corporation

About

Global Kinetics Corporation develops and commercializes the Parkinson’s KinetiGraph (PKG), a wearable system that continuously records Parkinson’s motor symptoms over multi-day periods to inform clinician treatment decisions.

Mission

Global Kinetics Corporation is a late-stage medtech company that developed the Parkinson’s KinetiGraph (PKG), a wearable device that continuously tracks symptoms of Parkinson’s disease. The PKG is designed to be worn for 6–10 days at a time, with the collected data used to better inform physicians on patient management and treatment. The company was founded in 2007 and originated from the Florey Institute in Melbourne. It was initially led by Malcolm Horne and is now headed by CEO John Schellhorn. Recently the company received a $7.75 million capital injection from the federal government’s Biomedical Translation Fund (BTM), reflecting its current funding event. Global Kinetics Corporation is an Australian health tech company. It raised $1.5 million through equity crowdfunding on the OurCrowd platform to kick-start its US expansion. The capital injection was described as the largest equity funding round in Australia to date. The raise comes amid preparations by local investors for the federal government to introduce a crowdsourced equity funding scheme. Under current regulations startups can only offer equity to sophisticated wholesale investors with more than $2.5 million in assets or earnings of around $250,000. The new framework is expected to allow startups to raise capital from small-scale retail investors and is expected to come into effect at the end of the 2015-16 financial year. Dan Bennett, Australian managing director of OurCrowd, said he would like the new framework to include an investment cap similar to other countries such as New Zealand. Global Kinetics Corporation develops the Parkinson’s KinetiGraph (PKG) System, a device-based system for managing Parkinson’s disease. The company was established in 2007 to commercialise the PKG. It plans to commercialise the technology after securing $3.5 million in equity funding and government grants. The PKG System was conceived, developed, funded and progressed to a commercial product within Victoria. The company’s leadership includes managing director Andrew Maxwell, chief scientific officer Malcolm Horne, chief technical officer Robert Griffiths, and national general manager Mary Taylor. Parkinson’s disease affects more than 15,000 Victorians, 65,000 Australians and 12 million people worldwide, representing the potential patient population for the PKG System.

Quick Facts